

Volume 33 Number 3 August 2006



THE CANADIAN JOURNAL OF **Neurological Sciences** LE JOURNAL CANADIEN DES Sciences Neurologiques





Polyglutamine Expansion

42nd ANNUAL CONGRESS

Canadian Neurological Sciences Federation (formerly CCNS)

> June 19-22, 2007 Edmonton, Alberta

EDITORIALS

259 Changes and Leadership at CJNS

REVIEW ARTICLES

- 260 Responsabilités Neuroéthiques (Version française) Eric Racine, Judy Illes
- 269 Neuroethical Responsibilities (English Version) Eric Racine, Judy Illes
- 278 Canadian Association of Neurosciences Review: Polyglutamine Expansion Neurodegenerative Diseases Ray Truant, Lynn A. Raymond, Jianrun Xia, Deborah Pinchev, Anjee Burtnik, Randy Singh Atwal

ORIGINAL ARTICLES

- 292 Propionibacterium Acnes Infections After Cranial Neurosurgery Michael E. Kelly, Darvl R. Fourney, Raphael Guzman, Venkatraman Sadanand Robert W. Griebel, Stephen E. Sanche
- 296 Bilateral Agenesis of the Hippocampal Dentate Gyrus in a Neurologically Normal Adult Arthur W. Clark, Harvey B. Sarnat
- 302 Rasmussen's Encephalitis in a 58-Year-Old Female: Still a Variant? Gary R. W. Hunter, Jeffrey Donat, William Pryse-Phillips, Sheri Harder, Christopher A. Robinson
- 306 Intractable Childhood Epilepsy and Maternal Fatigue Mohammed M.S. Jan
- 311 A Novel GDAP1 Mutation 439delA is Associated with Autosomal Recessive CMT Disease Domna-Maria Georgiou, Paschalis Nicolaou, David Chitayat, Pantelitsa Koutsou, Riyana Babul-Hirji, Jiri Vajsar, Jillian Murphy, Kyproula Christodoulou

NEUROIMAGING HIGHLIGHT

317 Submitted by: Lauren M. Segal, Angela Walker, Eric Marmor, Errol Stern, Mark Levental, Rafael S. Glikstein, Hyman M. Schipper

PEER REVIEWED LETTERS (See contents pages)

CORRESPONDENCE (See contents pages)

SUPPLEMENT 2

S1 12th Biennial Canadian Neuro-Oncology Meeting. May 26-28, 2006 Abstracts

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology https://doi.org/10.1017/S0317167100116397 Published online by Cambridge University Press


PM 40007777 R 9824

Real accuracy. Real results.

No other radiosurgery system for non-invasive brain surgery has the accuracy, stability and efficacy of Leksell Gamma Knife". Or the proof to back it up.

With over 2,000 peer-reviewed published articles, Leksell Gamma Knife[®] has an unmatched body of clinical evidence. Our accuracy is also unmatched, with a recent study demonstrating an average accuracy of 0.15 mm and a clinical accuracy (including imaging) of 0.48mm.

Read it for yourself. Get the Leksell Gamma Knife* Accuracy brochure at www.elekta.com/proof.





🛿 Stereotactic Neurosurgery 🛙 Gamma Knife surgery 📲 Functional Mapping 📲 Precision Radiation Therapy 📲 Image Guided Radiation Therapy 🖉 Stereotactic Rediation Therapy

ELEKTA



THE CANADIAN JOURNAL OF Neurological Sciences LE JOURNAL CANADIEN DES

Sciences Neurologiques

EDITORIALS

259 Changes and Leadership at CJNS Douglas Zochodne

REVIEW ARTICLES

- 260 Responsabilités Neuroéthiques (Version française) Eric Racine, Judy Illes
- 269 Neuroethical Responsibilities (English Version) Eric Racine, Judy Illes
- 278 Canadian Association of Neurosciences Review: Polyglutamine Expansion Neurodegenerative Diseases Ray Truant, Lynn A. Raymond, Jianrun Xia, Deborah Pinchev, Anjee Burtnik, Randy Singh Atwal

ORIGINAL ARTICLES

- 292 Propionibacterium Acnes Infections After Cranial Neurosurgery Michael E. Kelly, Daryl R. Fourney, Raphael Guzman, Venkatraman Sadanand, Robert W. Griebel, Stephen E. Sanche
- **296** Bilateral Agenesis of the Hippocampal Dentate Gyrus in a Neurologically Normal Adult *Arthur W. Clark, Harvey B. Sarnat*
- **302** Rasmussen's Encephalitis in a 58-Year-Old Female: Still a Variant?

Gary R. W. Hunter, Jeffrey Donat, William Pryse-Phillips, Sheri Harder, Christopher A. Robinson

- **306** Intractable Childhood Epilepsy and Maternal Fatigue *Mohammed M.S. Jan*
- 311 A Novel GDAP1 Mutation 439delA is Associated with Autosomal Recessive CMT Disease Domna-Maria Georgiou, Paschalis Nicolaou, David Chitayat, Pantelitsa Koutsou, Riyana Babul-Hirji, Jiri Vajsar, Jillian Murphy, Kyproula Christodoulou

NEUROIMAGING HIGHLIGHT

317 Submitted by: Lauren M. Segal, Angela Walker, Eric Marmor, Errol Stern, Mark Levental, Rafael S. Glikstein, Hyman M. Schipper

PEER REVIEWED LETTERS

- 320 Unilateral Hypoglossal Nerve Palsy Following the Use of the Laryngeal Mask Airway *Timothy S. Lo*
- 322 Occipital Condyle Fracture witrh Associated Hypoglossal Nerve Injury Shaan Chugh, Kambiz Kamian, Bart Depreitere, Michael L. Schwartz
- 325 Fibrous Dysplasia of the Skull Base Presenting Acutely in an Adult F. Amoozegar, A. Guberman
- 328 Sepsis from Neurofibromatosis Navdeep Tangri, Shireen Sirhan, Gordon Crelinsten
- 329 Pituitary Carcinoma with Subependymal Spread Krishna Kumar, Jefferson R. Wilson, Qiuyan Li, Ryan Phillipson
- 333 Correspondence
- 334 Books Received
- 334 Books Reviewed
- 337 Calendar of Events
- 338 Notes and Announcements
- A-5, A-6 Information for Authors
- A-25 Advertisers Index

SUPPLEMENT 2

S1 12th Biennial Canadian Neuro-Oncology Meeting May 26-28, 2006 Abstracts



THE CANADIAN JOURNAL OF Neurological Sciences LE JOURNAL CANADIEN DES Sciences Neurologiques

Editor-in-Chief/Rédacteur en chef Douglas W. Zochodne CALGARY, AB

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB Michael Shevell MONTREAL, QC G. Bryan Young LONDON, ON

Past Editors/Anciens rédacteurs en chef

James A. Sharpe TORONTO, ON Robert G. Lee CALGARY, AB Robert T. Ross WINNIPEG, MB (Emeritus Editor, Founding Editor)

Editorial Board/Conseil Scientifique

Timothy J. Benstead HALIFAX, NS J. Gregory Cairneross CALGARY, AB Richard Desbiens OUEBEC CITY, OC Ian Fleetwood HALIFAX, NS David Fortin SHERBROOKE, QC Hans-Peter Hartung DUSSELDORF, GERMANY Alan C. Jackson KINGSTON, ON Jack Jhamandas EDMONTON, AB Daniel Keene OTTAWA, ON Douglas Kondziolka PITTSBURGH, PA, USA Terence Myles CALGARY, AB David Ramsay LONDON, ON Guy Rouleau MONTREAL, OC Paul Steinbok VANCOUVER, BC Oksana Suchowersky CALGARY, AB Brian Toyota VANCOUVER, BC Brian Weinshenker ROCHESTER, MN, USA Samuel Wiebe CALGARY, AB Elaine Wirrell CALGARY, AB

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie Mark Hudon CALGARY, AB Richard Farb Neuropathological Conference/Conférence sur la neuropathologie David Ramsay LONDON, ON Book Review/Critiques de livres Andrew Kirk SASKATOON, SK Electronic Editor/Rédacteur d'électronique

Daniel Keene OTTAWA, ON

Journal Staff/Personnel de journal

Dan Morin, Chief Executive Officer Maggie McCallion, Designer/Production Coordinator Cindy Leschyshyn, Editorial Coordinator

Publications Committee/Comité de Rédaction

We acknowledge the assistance of the Government of Canada through the Publications Assistance Program towards our mailing costs. Canada Samuel Wiebe CALGARY, AB David Fortin SHERBROOKE, QC Asuri Prasad WINNIPEG, MB Richard McLachlan LONDON, ON The official journal of: / La Revue officielle de: The Canadian Neurological Society La Société Canadienne de Neurologie The Canadian Neurosurgical Society La Société Canadienne de Neurochirurgie The Canadian Society of Clinical Neurophysiologists La Société Canadienne de Neurophysiologie Clinique The Canadian Association of Child Neurology L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Congress of Neurological Sciences is at: Le secrétariat des quatre associations et du Congrès Canadien des Sciences Neurologiques est situe en permanence à: 7015 Macleod Trail SW, Suite 709, Calgary AB, Canada T2H 2K6.

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate for Individuals are: CS85 (Canada), USS85 (USA), and USS90 (elsewhere). Subscription rates for Institutions are: CS95 (Canada), USS95 (USA), and USS100 (elsewhere). Resident, intern and student rates are available. See www.cjms.org for details. Single copies CS24 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, PO. Box 3456, Station A, Calgary, AB Canada T2H 1X8. Courier to: 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. Email: journal@cjms.org; Website: www.cjms.org COPYRIGHT® 2006 by THE CANADIAN JOURNAL OF NEUROLOGICAL

COPÝRIGHTO 2006 by THE CANADÍAN JÓURNAL OF NEUROLOGICAL SCIENCES INC, All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mai Agreement no: 40007777; PAP Registration no: 09824. Postage paid at Calgary, Alberta. This journal is indexed by Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences and Fisheries Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences, Current Contents (Clinical Medicine and Life Sciences), Dental Index, e-psyche, Excerpta Medica, Index Medicus, Index to Scientific Reviews, Journal Watch Neurology, Laboratory, Hacards Bullentin, Leisure, Recreation and Tourism Abstracts, MEDLINE, Neurosciences Citation Index, Nutrition Abstracts and Reviews, Nutrition Research Newsletter, Pharmaeconomics and Outcome News, Psychological Abstracts, Recitons Weekly, Referativnyi Zhurnal, Review of Medical and Veterinary Mycology, Science Citation Index, Weed Abstracts.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 85 SC (non-membres au Canada): 85 SÉ-U (Etats Unis) et 90 SÉ-U (ailleurs): l'abonnement annuel for pour les institutions est de 95 SC (nonmembres au Canada): 95 SÉ-U (Etats Unis) et 100 SÉ-U (ailleurs): Internes, résidents, fellows pré et post doctoral voir www.cjns.org pour détails. Copie simple: 24 SC plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques. PO. Bos 5456. Station A, Calgary, AB Canada T2H 1X8. Par courrier: 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. Email journal@cjns.org; Website: www.ejns.org DROITS D'AUTEUR® 2006: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce

DROITS D'AUTEUR© 2006: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'authorisation du Journal Canadien des Sciences Neurologiques. Posté sous poste-publications: numéro de convention: 40007777; numéro d'enregistrement PAP 09824. Port payé à Calgary, Alberta. Le Journal est cife et indexé dans Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences and Fisheries Abstracts, MCA-Automatic Subject Citation Alert, Biological Abstracts, BIOBASE, BIOSIS, Chemical Abstracts Current Awareness in Biological Sciences. Current Contents (Clinical Medicine and Life Sciences), Dental Index, e-psyche, Excerpta Medica, Index Medicus, Index to Scientific Reviews, Journal Watch Neurology, Laboratory Hazards Bullentin, Leisure, Recreation and Tourism Abstracts, MEDLINE, Neurosciences Citation Index, Nutrition Abstracts and Reviews, Nutrition Research Newsletter, Pharmacconomics and Outcome News, Psychological Abstracts, Reactions Weekly, Referativnyi Zhurnal, Review of Medical and Weterinary Mycology, Science Citation Index, Week Abstracts.

Advertising representative/Représentant de publicité: Jhoanna Del Rosario, Corporate Development Coordinator Tel (403) 229-9575 Fax (403) 229-1661 E-mail: journal@cjns.org; Web Site: www.cjns.org

Printer/Imprimeur: Sundog Printing Limited, 1311 Ninth Avenue SW Calgary, Alberta T3C 0H9

ISSN 0317 - 1671



PORTRAIT OF A FAMILY HISTORY

HISTORY DOESN'T HAVE TO REPEAT ITSELF

Roger, History of angina.

Died age 57 of MI.

Help Reduce the Risk of CV Death

(p<0.001; 6.1% vs. 8.1%) ALTACE 10 mg. The proven CV risk reduction dose.¹

by

Alice, History of diabetes and hypercholesterolemia.

Died age 62 of complications related to stroke.



GUARDING AGAINST CV DEATH

Altace is indicated in the treatment of essential hypertension, normally when beta-blockers and diuretics are inappropriate. It may be used alone or in association with thiazide diuretics. Altace is indicated following acute myocardial infarction in clinically stable patients with signs of left ventricular dysfunction to improve survival and reduce hospitalizations for heart failure.

Altace may be used to reduce the risk of MI, stroke or CV death in patients over age 55 who are at high risk of CV events because of a history of CAD, stroke, peripheral artery disease or diabetes accompanied by at least 1 other CV risk factor such as hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking or documented microalbuminuria.

Like other ACE inhibitors, Altace is not recommended for pregnant or lactating women and should be used with caution in patients with renal insufficiency. The most frequent adverse events occurring in clinical trials with Altace monotherapy in hypertensive patients who were treated for at least 1 year (*n*=651) were: headache (15.1%), dizziness (3.7%), asthenia (3.7%) and chest pain (2.0%). Discontinuation of therapy due to clinical adverse events was required in 5 patients (0.8%). In the HOPE study, the reasons for stopping treatment were cough (ramipril 7.3% vs. placebo 1.8%), hypotension/dizziness (ramipril 1.9% vs. placebo 1.5%) and edema (ramipril 0.4% vs. placebo 0.2%).

ALTACE is the most prescribed ACEI in Canada and the ACEI most prescribed by cardiologists.^{*}

*IMS Health Canada: Canadian CompuScript Audit, Moving Annual Total ending December 2005, Total Dispensed Prescriptions.

 PAAB
 Product Monograph available to physicians and pharmacists upon request.

 CDN.RAM.06.02.02E
 CDN.RAM.06.02.02E

New indication based on the **CARDS**[§] Trial Results[†]

Trusted Power for You and Your Patients

and hypertension without CHD but with other risk factors¹

PTOP offers up to 50% LDL-C reduction at starting doses of 10, 20 and 40 mg^{1¥} ¥ When a >45% LDL-C reduction is required, patients may be started at 40 mg o.d. Power

AND is indicated to reduce the risk of MI and stroke in patients with type 2 diabetes

Evidence

ONLY LIPITOR' is supported by 5 million patient-years of therapy in Canada^{2£} Trust

LIPITOR is an HMG-CoA reductase inhibitor (statin). LIPITOR is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol (total-C), LDL-C, TG and apolipoprotein B (apo B) in hyperlipidemic and dyslipidemic conditions (including primary hypercholestero-lemia, combined [mixed] hyperlipidemia, dysbetalipoproteinemia, hypertriglyceridemia and familial hypercholesterolemia) when response to diet and other non-pharmacological measures alone has been inadequate

LIPITOR also raises HDL-cholesterol and therefore lowers the LDL-C/HDL-C and total-C/HDL-C ratios (Fredrickson Type IIa and IIb dyslipidemia).

LIPITOR is indicated to reduce the risk of myocardial infarction in adult hypertensive patients without clinically evident coronary heart disease, but with at least three additional risk factors for coronary heart disease such as age ≥55 years, male sex, smo-king, type 2 diabetes, left ventricular hypertrophy, other specified abnormalities on ECG, microalbuminuria or proteinuria, ratio of plasma total cholesterol to HDL-cholesterol ≥6 or premature family history of coronary heart disease

† LIPITOR is also indicated to reduce the risk of myocardial infarction and stroke in adult patients with type 2 diabetes mellitus and hypertension without clinically evident coro-

d/or TG levels to	achieve
at the lowest	PAAB
rely hypercho- nally impaired.	Member

PAAB	Kirkland, Quebec H9J 2M5
Member R&D	

LIPITOR and with other HMG-CoA reductase inhibitors.

Patients who develop any signs or symptoms suggestive of myopathy should have their CK levels measured. LIPITOR therapy should be discontinued if markedly elevated CK levels are measured or myopathy is diagnosed or suspected

See Prescribing Information for complete warnings, precau-tions, dosing and administration.

Less than 2% of patients discontinued therapy due to adverse experiences. Most common adverse effects vs. placebo occurring in patients at an incidence ≥1% were constipation (1% vs. 1%), diarrhea (1% vs. 1%), dyspepsia (1% vs. 2%), flatulence (1% vs. 2%), nausea (1% vs. 0%), headache (1% vs. 2%), pain (1% vs. <1%), myalgia (1% vs. 1%) and asthenia (1% vs. <1%). The adverse events reported in ≥1% of boys and postmenarchal direction (1% vs. 1%) users of devenied neit determined neit determi girls (10-17 years of age) were abdominal pain, depression and headache

LIPITOR is contraindicated: During pregnancy and lactation; active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal; hypersensitivity to any component of this medication.

The dosage of LIPITOR should be individualized according to the baseline LDL-C, total-C/HDL-C ratio and/or TG levels to achieve

November 2005. 2. IMS Health, IMS MIDAS™ (Standard Units: Year 1997 through to April 2005 nical Trials, 1999, John Wiley & Sons Ltd. 137-38

elderly or are concomitantly being administered digoxin or CYP 3A4 inhibitors.

20 mg

atorvastatin calcium

power you can trust

80 mg

40 mg

Liver function tests should be performed before the initiation of treatment, and periodically thereafter.

If increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) show evidence of progression, par-ticularly if they rise to greater than 3 times the upper limit of normal and are persistent, the dosage should be reduced or the drug discontinu

LIPITOR, as well as other HMG-CoA reductase inhibitors, should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver

§ CARDS = Collaborative Atorvastatin Diabetes Study.

£ A patient-year represents the total time of exposure to LIPITOR as defined by the sum of each patient's time on LIPITOR.3



References: 1. LIPITOR (atorvastatin calcium) Product Monograph, Pfizer Canada Inc.,

Life is our life's work

November 2005. 2. IMS Health mellitus and hypertension without clinically evident coronary heart disease, but with other risk factors such as age \geq 55 years, retinopathy, albuminuria or smoking.

baseline LDL-C, total-C/HD

Very rare cases of rhabdomyolysis with acute renal fail-ure secondary to myoglobinuria have been reported with

the recommended target dose needed to achieve L

Caution should be exerci lesterolemic patients who

NOW AVAILABLE on the Quebec formulary

Neuropathic Pain Scalded From Within

LYRICA is indicated for the management of neuropathic pain associated with¹:

R

- Diabetic peripheral neuropathy
- Postherpetic neuralgia

New

Demonstrated **fast, sustained** neuropathic pain relief

Ĩ

PREGABA

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events (twice the rate as that seen with placebo) were dose related for PHN and DPN patients in the recommended dose range of 150 mg/day to 600 mg/day: dizziness (9-37%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%) and dry mouth (1.9-14.9%).

Dosage reduction is required in patients with renal impairment as pregabalin is primarily eliminated by renal excretion.

- ¥Pharmacodynamic interactions were reported with oxycodone, lorazepam, ethanol and thiazolidinedione antidiabetic agents. Please consult Prescribing Information for complete interaction information.
- Please see Prescribing Information for complete Warnings and Precautions, Dosage and Administration, and patient selection criteria.
- † A 13-week, multicentre, double-blind, placebo-controlled trial in 368 patients with PHN. A significant difference was shown over placebo for all doses: 150 mg/day, 300 mg/day, and 600 mg/day at week 1, p<0.001 for pain and p<0.01 for sleep.</p>
- [‡] A 12-week, multicentre, randomised, double-blind, placebo-controlled study in 338 patients with neuropathic pain (DPN [n=249] or PHN [n=89]), resulting in a significant difference from placebo in the flexible dose range 150-600 mg/day (p≤0.05, week 2 and p≤0.01, weeks 3-12), and the fixed dose of 600 mg/day (p≤0.05, week 1 and p≤0.01, weeks 2-12).

- Rapid neuropathic pain relief shown in patients with PHN as early as Week 1^{2†}
- Sustained neuropathic pain relief demonstrated over 3 months^{3‡}
- Rapid improvement in pain-related sleep interference observed in patients with PHN as of Week 1^{2†}
- No clinically significant pharmacokinetic drug interactions reported¹¥
- Simple dosing regimen¹





*TM C.P. Pharmaceuticals International C.V. Pfizer Canada Inc., licensee



For brief prescribing informati see pages A-18, A-19, A-20, A-

g/10.1017/S0317167100116397



Treatment for Spinal Fractures is as Individual as your Patients

Because not all fractures are created equal.

Kyphon offers a complete family of fracture reduction instruments, each designed to address individual patient anatomy and fracture morphology.

KyphX[®] |Xpander[®]

INFLATABLE BONE TAMP



This standard balloon offers fracture reduction capabilities by enabling accurate balloon placement and effective inflation geometry.

KyphX[®] | Exact[™] INFLATABLE BONE TAMP

Uniquely constructed to provide uni-directional balloon inflation for focused fracture reduction. This balloon is recommended for wedge or concave fractures with singleendplate involvement.



KyphX[®] |Latitude™ CURETTE



Intended to scrape and score cancellous bone in the spine. May be used as an adjunctive device with Kyphon's fracture reduction instruments.


> KyphX[®] | Elevate[™] INFLATABLE BONE TAMP

Provides single-plane preferential inflation resulting in 50% greater superior/inferior profile in comparison to the medial/lateral profile. This balloon is recommended for bi-concave or wedge fractures with involvement of both endplates.



KyphX[®] | **Express**™

INFLATABLE BONE TAMP



To learn more about expanding your options for fracture reduction, call 1-877-459-7466.

Although the complication rate with kyphoplasty has been demonstrated to be low, as with most surgical procedures, there are risks associated with kyphoplasty, including serious complications. For complete information regarding indications for use, warnings, precautions, adverse events and methods of use, please reference the devices' Instructions for Use. *Kyphon, KyphX* and *KyphX Xpander* are registreed trademarks of Kyphon Inc. *Elevate, Exact, Express, Laitude* and *Ahead of the Curve* are trademarks of Kyphon Inc. ©2005 Kyphon Inc. All rights reserved. 16000500-01



NAME CHANGE

Canadian Congress of Neurological Sciences

to

Canadian Neurological Sciences Federation

Recently our name was officially changed to the Canadian Neurological Sciences Federation to better reflect the fact that we represent a federation of four professional societies. Our official announcement and changes to our logo, website, etc. are coming shortly.





Join us in Edmonton, Alberta for the **42nd Annual Congress** presented by the **Canadian Neurological Sciences Federation** (CNSF) June 19-22, 2007



In a major clinical trial, Betaseron[®] patients[†] experienced:

- 31% reduction in annual exacerbation rate vs. the placebo group (p=0.0001)^{1,‡}
- Significant reduction in moderate or severe attacks per year vs. the placebo group (p=0.001)^{1,6}
- Significantly fewer lesions on MRI (p=0.0001)^{1,**}

16-year study ongoing²

The MS Pathways[™] support program offers Betaseron[®] patients a caring and convenient approach to MS therapy – right from the start

- Multilingual nurse telephone support line for personalized assistance
- In-home Betaseron[®] injection training program
- Medical travel assistance and related services

*Double-blind, multi-clinic (11 site) randomized, parallel, placebo-controlled clinical investigation, two-year duration, subjects received 1.6 MIU Betaseron® (n=125), 8 MIU Betaseron® (n=124) or placebo (n=123). Treated with 8 MIU Betaseron®, self-administered, every other day.

\$Mean of 19.5 moderate or severe exacerbation days per patient vs. 41.1 days ** 0.9% decrease in MRI lesion area vs. 21.4% increase in placebo group



Act early. Act strong.

BETASERON[®] (interferon beta-1b) is indicated for the reduction of the frequency of clinical exacerbations in ambulatory patients with relapsing-remitting multiple sclerosis (RRMS) and for the slowing of the progression in disability and the reduction of the frequency of clinical exacerbations in patients with secondary-progressive multiple sclerosis (SPMS). The safety and efficacy of BETASERON[®] in primary-progressive MS (PPMS) have not been evaluated. Efficacy of treatment for longer than two years has not been substantially demonstrated in RRMS. The most common side effects related to BETASERON[®] in patients with RRMS are: flu-like symptom complex (76%); fever (59%); chills (46%); injection site reactions (85%); myalgia (44%); asthenia (49%) and malaise (15%).

For complete warnings and precautions, please refer to the product monograph available to healthcare professionals upon request. References: 1. Betaseron[®] Product Monograph, June 2004. 2. Data on file. Berlex Canada Inc.



Berlex Canada Inc. Pointe-Claire, Québec H9R 5W





1913A00/02.2006



EMG EP EEG PSG Ambulatory EEG IOM

Evoke your potential Évoquez votre potentiel

Thank you for visiting our booth at the CCNS ! Merci d'avoir visité notre kiosque au CCNS !

nttps://doi.org/10.1017/50317167100116397 Publ Carlie Carl

HC / CANNABINOIDS THC / CANNABINOIDS / THC / CANNABINOIDS RINOIDS CANNABINOIDS T **CANNABINOIDS** THC / CANNABINOIDS **ANNABINOIDS** / THC THC / CANNABINOIDS CANNARINOIDS CANNABINOIDS **CANNABINOIDS** ANNABINOIDS THC S

CANNABINOIDS / THC / CANNABINOIDS / THC / CANNABINOIDS / THC / CANNABINOIDS / THC / CANNABINOIDS / THC ANNABINOIDS / THC / CANNABINOIDS / THC / CANNABINOIDS / THC ANNABINOIDS / THC / CANNABINOIDS / THC ANNABINOIDS / THC / CANNABINOIDS / THC ANNABINOIDS / THC ANNAB

THC

SHOULDN'T YOU CONSIDER "CESAMET®?

***CESAMET** is a THC-analog that binds to cannabinoid receptors.^{12t}

*CESAMET has a BID dosing with dose flexibility as it comes in standardized and quality controlled 0.5 mg and 1 mg capsules." ***CESAMET** is a controlled drug.¹ It is prescribed and distributed by recognized health professionals.

***CESAMET** is a synthetic form of THC available on the Canadian market since 1981.


CANNABINOIDS

† Clinical significance has not been established.

IDS

тнс

NNABINOIDS



"CESAMET is contraindicated in patients with known sensitivity to marijuana or other cannabinoid agents, and in those with a history of psychotic reactions.

"CESAMET should be used with extreme caution in patients with severe liver dysfunction and those with a history of non-psychotic emotional disorders.

The most frequently observed adverse reations to nabilone and their incidences reported in the course of clinical trials were: drowsiness (66%), vertigo (58.8%), psychological high (38.8%) and dry mouth (21.6%). Please consult prescribing information for full warnings, precautions, adverse events and administration.

VALEAN T

HC /

N T ® Registered trademark of Valeant Canada Limited Apr. 2005

PAAB



BID Cannabinoid Therapy



Betaseron[®] Efficacité à long terme éprouvée^{*}

Durant une étude clinique d'importance, les patients' prenant Betaseron ont présenté :

- une réduction de 31% de leur taux annuel de poussées par rapport aux patients du groupe placebo (p = 0,0001)¹¹
- une diminution significative du nombre annuel de leurs poussées modérées ou graves par rapport aux patients du groupe placebo (p = 0,0001)^{1,6}
- un nombre significativement moindre de lésions observables à l'IRM (p = 0,0001)ⁿ

Étude en cours depuis 16 ans²

SEP LeParcours offre aux patients atteints de SEP prenant Betaseron un programme de soutien à visage humain et une démarche thérapeutique pratique – dès le début

- · Ligne d'aide où du personnel infirmier multilingue offre un service personnalisé
- Programme de formation à domicile sur l'injection de Betaseron
- Assistance médicale en voyage et services associés

 Étude clinique multicentrique (11 centres) parallèle, randomisée, à double insu et contrôlée par placebo, d'une durée de deux ans, menée auprès de patients recevant 1,6 MUI de Betaseron (n = 125), 8 MUI de Betaseron (n = 124) ou un placebo (n = 123).

† Traités par 8 MUI de Betaseron auto-administrés tous les deux jours

‡ 0,9 vs 1,31

Moyenne de 19,5 jours de poussées modérées ou graves par patient vs 41,1 jours
 Diminution de 0,9% de l'étendue des lésions observables à l'IRM vs une augmentation de 21,4% dans le

Uminution de 0,9% de letendue des lesions observables à l'IKM vs une augmentation de 21,4% dans le groupe placebo

BETASERON (interféron bêta-1b) est indiqué pour réduire la fréquence des poussées cliniques chez les patients ambulatoires atteints de sclérose en plaques rémittente (SEP) et pour ralentir la progression de l'incapacité et réduire la fréquence des poussées cliniques chez les patients atteints de SEP progressivesecondaire. L'efficacité et l'innocuité de BETASERON dans la SEP progressive-primaire n'ont pas été évaluées. On ne dispose pas de données probantes sur l'efficacité du traitement de la SEP rémittente au-delà de deux ans. Chez les patients atteints de SEP rémittente, les effets indésirables les plus courants liés à l'utilisation de BETASERON sont : syndrome pseudo-grippal (76 %) ; fièvre (59 %) ; frissons (46 %) ; réactions au point d'injection (85 %) ; myalgie (44 %) ; asthénie (49 %) et malaise (15 %).

Pour plus de renseignments sur les mises en garde et les précautions, veuillez consulter la monographie du produit fournie sur demande aux professionnels de la santé. Références : 1. Monographie de Betaseron, juin 2004. 2. Données internes. Berlex Canada inc.

(RED) CCPP





1913F00/02.2006



RON BÊTA-16

Agir tôt. Agir en force.